Reata Pharmaceuticals Inc - Class A

RETA

$109.77

+1.9% (1 year change)

Market Cap

$3.48 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$76.34 - $186.82

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-12.84x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $3.48 Billion
Enterprise Value $2.73 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +1.9%
52-Week High $186.82
52-Week Low $76.34
Beta 1.07
Outstanding Shares 31.5 Million
Avg 30 Day Volume 174 Thousand

Valuation

P/E Ratio -12.84
PEG -33.93
Earnings per Share -$7.71
Price to Sales Ratio Infinity
Price to Book Ratio 12.2
Revenue to Enterprise Value 316.84
EBIT to Enterprise Value -12.76
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $8.61 Million
Gross Profit $8.61 Million
EBIT -$214 Million
Net Income -$266 Million
Profit Margin -3092.54%
Quarterly Earnings Growth (YoY) +37.8%
Return on Equity -84.84%
Return on Assets -34.24%
Return on Invested Capital -32.58%

News

Corriente Advisors, LLC Buys Coinbase Global Inc, Reata Pharmaceuticals Inc, QuantumScape Corp, ...

Corriente Advisors, LLC Buys Coinbase Global Inc, Reata Pharmaceuticals Inc, QuantumScape Corp, ...

Related Stocks: COIN , RETA , QS , LTRN , KTOS , MP , TDY , TFFP , FB , EYPT ,

GuruFocus GuruFocus, about 1 month ago
Reata''s Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application

Reata''s Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application

Reata Pharmaceuticals Inc (NASDAQ: RETA ) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome. The FDA completed a bio-research ...

Benzinga Benzinga, about 2 months ago
Reata Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

Reata Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha Seeking Alpha, about 2 months ago